LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
deoxyribonucleic acid (DNA) A polymeric nucleic acid molecule composed of a series of covalently linked deoxyribonucleotides, each of which incorporates one of four nucleobases: adenine (A), guanine (G), cytosine (C), and thymine (T). DNA is most often found in double-stranded form, which consists of two complementary, antiparallel nucleotide chains in which each of the nucleobases on each individual strand is paired via hydrogen bonding with one on the opposite strand; this structure commonly assumes the shape of a double helix. DNA can also exist in single-stranded form. By storing and encoding genetic information in the sequence of these nucleobases, DNA serves as the universal molecular basis of biological inheritance and the fundamental template from which all proteins, cells, and living organisms are constructed.
A heterozygous mutation is a mutation of only one allele. A homozygous mutation is an identical mutation of both the paternal and maternal alleles. Compound heterozygous mutations or a genetic compound consists of two different mutations in the paternal and maternal alleles.
Ponting later stated that Stanley had asked Thatcher to overrule Heseltine on the matter; he withheld information not just from Dalyell but from the Commons Foreign Affairs Committee, which was conducting its own inquiry, citing national security considerations. Six days after Heseltine's letter to Denzil Davies, Ponting sent Davies an anonymous note stating that the letter had been written according to the advice of John Stanley, but contrary to the advice of civil servants, and suggesting other potential lines of inquiry. Three months later he sent two documents exposing the alleged cover up. Heseltine strongly supported, and by some accounts pushed for, the prosecution of Ponting (Ministry of Defence police had advised against, but the Solicitor-General Sir Patrick Mayhew urged that he should be). Heseltine later said that Thatcher had not been involved in the decision to prosecute. Neither Heseltine nor Stanley were called as witnesses at Ponting's trial in January 1985 (Richard Mottram, Heseltine's private secretary, gave evidence on behalf of the Ministry of Defence). To general surprise Ponting was acquitted. A week later Heseltine launched a stinging seventy-minute attack on Ponting in the House of Commons, and a year later he walked out of a Channel 4 News studio on being told that a recorded interview with Ponting was also to be shown. Stanley was seen as the villain of the piece, whereas Heseltine had merely declined to correct false statements made by others.
=== Imprinting === Molecular imprinting describes a process by which a host is constructed from small molecules using a suitable molecular species as a template. After construction, the template is removed leaving only the host. The template for host construction may be subtly different from the guest that the finished host binds to. In its simplest form, imprinting uses only steric interactions, but more complex systems also incorporate hydrogen bonding and other interactions to improve binding strength and specificity.
The potency of cultivated specimens can vary widely per each flush (harvest). In a classic paper published by Jeremy Bigwood and M.W. Beug, it was shown that with each flush, psilocybin levels varied somewhat unpredictably but were much the same on the first flush as they were on the last flush; however, psilocin was typically absent in the first two flushes but peaked by the fourth flush, making it the most potent. Two strains were also analyzed to determine potency in caps and stems: In one strain the caps contained generally twice as much psilocybin as the stems, but the small amount of psilocin present was entirely in the stems. In the other strain, a trace of psilocin was present in the cap but not in the stem; the cap and stem contained equal amounts of psilocybin. The study concluded that the levels of psilocybin and psilocin vary by over a factor of four in cultures of P. cubensis grown under controlled conditions.
Sources: en.wikipedia.org
==== 2006–2011: Stadium move and transition ==== In the summer of 2006, Wenger oversaw Arsenal's relocation to the Emirates Stadium. During the construction phase, he described the move as "vital" to the club's financial future and believed Arsenal were better able to attract the best players. Moving to the new stadium, however, presented several problems in the short term, as the club prioritised financing it over the team. Wenger sold some of his experienced players such as Campbell, Lauren and Pires, sanctioned Cole's move to Chelsea in part exchange for defender William Gallas, and integrated young players like Theo Walcott and Alex Song into the first team. His youthful team contested the League Cup final in February 2007 and were the youngest to play in a major English cup final, averaging 21 years. They ultimately came up short against Chelsea, who won the match 2–1. Arsenal finished fourth in the 2006–07 league season; Wenger had ruled out their title chances following defeat to Bolton in November 2006. The team's lack of directness and efficiency of possession was a familiar theme during the campaign; Guardian journalist Daniel Taylor observed two matches into the league season: "The most watchable side are frequently the most frustrating. Arsenal are wonderfully incisive yet infuriatingly blunt."
US-India ties began to strain in April 2021 when India faced a massive spike in COVID-19 infections. The US had invoked the Defense Production Act of 1950 to ban the export of raw materials needed to produce vaccines in order to prioritize domestic vaccine production. According to The Times of India, this also caused an explosion of anti-US sentiment in India, as the U.S. had vaccine reserves and refused to share COVID-19 vaccine patents. This came after a plea by Adar Poonawalla, CEO of the Serum Institute of India, to lift the embargo on export of raw materials needed to ramp up production of COVID-19 vaccines, was rejected. However, in late April, right after a phone call with Ajit Doval, the National Security Advisor of India, the Biden administration stated it would make raw materials necessary for production of the Oxford–AstraZeneca COVID-19 vaccine available to India, and began to send more than ₹714 crore (equivalent to ₹874 crore or US$91 million in 2026) worth of drug treatments, rapid diagnostic tests, ventilators, personal protective equipment, and mechanical parts needed to manufacture vaccines to India, along with a team of public health experts from the United States Centers for Disease Control and Prevention. The US also stated that it planned to finance the expansion of Biological E. Limited, an Indian-based COVID-19 vaccine production company. India entered negotiations with the US after it declared that it would share 60 million Oxford-AstraZeneca vaccines with the world.
=== Transport of hydrogen ions === Some oxyhemoglobin loses oxygen and becomes deoxyhemoglobin. Deoxyhemoglobin binds most of the hydrogen ions as it has a much greater affinity for more hydrogen than does oxyhemoglobin.
Concanavalin A (ConA) is a lectin (carbohydrate-binding protein) originally extracted from the jack-bean (Canavalia ensiformis). It is a member of the legume lectin family. It binds specifically to certain structures found in various sugars, glycoproteins, and glycolipids, mainly internal and nonreducing terminal α-D-mannosyl and α-D-glucosyl groups. Its physiological function in plants, however, is still unknown. ConA is a plant mitogen, and is known for its ability to stimulate mouse T-cell subsets giving rise to four functionally distinct T cell populations, including precursors to regulatory T cells; a subset of human suppressor T-cells is also sensitive to ConA. ConA was the first lectin to be available on a commercial basis, and is widely used in biology and biochemistry to characterize glycoproteins and other sugar-containing entities on the surface of various cells. It is also used to purify glycosylated macromolecules in lectin affinity chromatography, as well as to study immune regulation by various immune cells.
Al-Hijri also urged the "remnants" of armed opposition members to surrender, promising that those who do so will be under the protection of the spiritual leadership and "will not be humiliated or mistreated". There were protests in Jaramana with protestors chanting slogans against president Ahmed al-Sharaa and his government. The Syrian army began withdrawing from Suwayda. A statement by the Syrian Ministry of Defense said the withdrawal came after the army had completed operations against "outlaw groups" in the city. State news agency SANA reported the pullout was in line with the deal reached between the government and Druze religious leaders. On 17 July, following the withdrawal of the Syrian army, Druze fighters reportedly discovered entire houses had been set on fire, families slaughtered inside homes, and looting. Witnesses in Suwayda compared the Syrian government's actions to summary executions. clashes between Bedouin and Druze fighters were also reported in the western countryside of Rif Dimashq Governorate. Clashes resumed in Suwayda after government forces withdrew as Bedouins launched new armed assaults on Druze forces, with the stated goal of releasing Bedouin prisoners of war. A Bedouin commander told Reuters that the ceasefire agreement did not bind his men, but only the forces of President Ahmed al-Shara's administration. According to the commander, his forces are aiming to free the Bedouins who were detained in recent days by the Druze fighters.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.